Mechanisms of Response and Resistance to Combination Decitabine and Ipilimumab for Transplant Naïve and Post-Transplant AML/MDS
Livius Penter(Dana-Farber Cancer Institute), Catherine J. Wu(Dana-Farber Cancer Institute), Jerome Ritz(Dana-Farber Cancer Institute), Magdalena Thurin(Center for Cancer Research), Jacquelyn O. Wolff(Dana-Farber Cancer Institute), Rebecca Leonard(Dana-Farber Cancer Institute), Aashna Jhaveri(Dana-Farber Cancer Institute), Jennifer Altreuter(Dana-Farber Cancer Institute), Stephen Hodi(Dana-Farber Cancer Institute), Manishkumar Patel(Icahn School of Medicine at Mount Sinai), Srinika Ranasinghe(Dana-Farber Cancer Institute), Taylor Robertson(Dana-Farber Cancer Institute), Helen Chen(IQVIA (United States)), Seunghee Kim‐Schulze(Icahn School of Medicine at Mount Sinai), Len Taing(Dana-Farber Cancer Institute), Kenneth J. Livak(Broad Institute), Carrie Cibulskis, Scott J. Rodig(Brigham and Women's Hospital), Stacey Gabriel(Broad Institute), Robert J. Soiffer(Dana-Farber Cancer Institute), Giacomo Oliveira(Dana-Farber Cancer Institute), Kathleen L. Pfaff(Dana-Farber Cancer Institute), Sacha Gnjatic(Tisch Hospital), Nicoletta Cieri(Broad Institute), Jackson Southard(Dana-Farber Cancer Institute), Howard Streicher(National Cancer Institute), Franziska Michor(Dana-Farber Cancer Institute), Yang Liu(Mudanjiang Medical University), Lin Yang(Yunnan Agricultural University), Shuqiang Li(Broad Institute), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Nicole Cullen(Dana-Farber Cancer Institute), Donna Neuberg(Otsuka (Japan))
Cited by 2